Loading stock data…
AZN.L
LSE13,502pGBX+158.00p (+1.18%)
Market ClosedLast close May 11
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at 13,502p. The stock is currently , remaining 1.4% above its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why AZN.L maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price13,502p
Potential Downside
24.2%
Whystock Fair Value10,236p
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Buy
Mean target16,305p+20.8%
Range11,127p – 18,583p
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$223.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.77
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
162.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.84%
Volume
Today's trading volume
0
Recent News
AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug
AstraZeneca PLC (NYSE:AZN) is among the Best Biotech Stocks. On May 1, CNBC reported that an FDA advisory panel voted 6-3 against allowing AstraZeneca PLC (NYSE:AZN)’s oral breast cancer drug camizestrant. This action resulted in the company’s London-listed shares falling 2% Friday morning. Panel members voting against the drug concluded that the SERENA-6 study failed to […]
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript
Gaia Vasiliver-Shamis: Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. Joining me on today’s call are Thane Wettig, chief executive officer, David DeLucia, chief financial officer, and Carol Gaddum, vice president of product development. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results, and results of operations, risks related to our business, and certain other business matters.
PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact
Exploring PRIMECAP Management (Trades, Portfolio)'s Recent 13F Filing and Investment Strategies
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. AstraZeneca PLC is among the best cancer stocks on this list. TheFly reported on May 6 that CDT Equity announced that AZD5904, a selective inhibitor of human myeloperoxidase originally licensed from AstraZeneca PLC (NYSE:AZN), has entered the Patent […]
How AstraZeneca Plans to Hit $80 Billion in Revenue and Expand in the U.S.
The U.K. drugmaker recently direct-listed its shares in the U.S., betting on a new-drug pipeline to achieve its revenue target by 2030.